论文部分内容阅读
目的观察DDGP方案(顺铂、地塞米松、吉西他滨、培门冬酶)治疗初治结外自然杀伤/T细胞淋巴瘤(extranodal natural killer/T-cell lymphoma,ENKL)的临床疗效及安全性。方法初治ENKL患者18例,均采用DDGP方案治疗:顺铂20mg/m2,第1~4天;地塞米松12mg/m~2,第1~5天;吉西他滨800mg/m~2,第1、8天;培门冬酶2 500u/m~2,第1天;21d为1个治疗周期,中位随访时间39个月,评价疗效及不良反应。结果 18例患者治疗1个月后,完全缓解15例,部分缓解3例,总有效率100%;治疗6个月后复发5例,其中3例死亡;13例无病生存;出现3/4度白细胞或中性粒细胞减少12例,血小板减少10例,贫血5例,未发生致死性血液毒性反应,无严重过敏反应、胰腺炎及血糖异常。结论DDGP方案治疗初治ENKL疗效好,不良反应发生率低,安全性高。
Objective To observe the clinical efficacy and safety of DDGP regimen (cisplatin, dexamethasone, gemcitabine and pegaspargase) in the treatment of extranodal natural killer / T-cell lymphoma (ENKL). Methods 18 patients with newly diagnosed ENKL were treated with DDGP regimen: cisplatin 20mg / m2, 1st to 4th days, dexamethasone 12mg / m2, 1st to 5th days, gemcitabine 800mg / m2, , 8 days; pestinase 2 500u / m ~ 2, the first day; 21d for a treatment cycle, the median follow-up time of 39 months to evaluate the efficacy and adverse reactions. Results After 18 months of treatment, 15 cases were completely relieved and 3 cases partially relieved. The total effective rate was 100%. Five cases were relapsed after 6 months of treatment, of which 3 were dead, 13 were disease-free, and 3/4 12 cases of leukopenia or neutropenia, 10 cases of thrombocytopenia, 5 cases of anemia, no lethal hematological toxicity, no serious allergic reaction, pancreatitis and abnormal blood glucose. Conclusion DDGP regimen has good curative effect on initial treatment of ENKL with low incidence of adverse reactions and high safety.